期刊文献+

高效液相色谱法测定非布司他片的含量 被引量:5

Content Determination of Febuxostat Tablets by HPLC
下载PDF
导出
摘要 目的建立测定非布司他片含量的高效液相色谱法。方法色谱柱为Kromasil-C18柱(250 mm×4.6 mm,5μm),流动相为甲醇-0.05%磷酸溶液(80∶20),流速为1.0 mL/min,检测波长为317 nm。结果非布司他质量浓度在32.4~48.6μg/mL范围内与峰面积线性关系良好(r=0.999 0),平均回收率为99.58%,RSD=1.13%。结论该方法简便快速,灵敏、准确,适用于测定非布司他片中非布司他的含量,可作为非布司他制剂的质量控制方法。 Objective To establish an HPLC method for the determination of Febuxostat Tablets. Methods The method was pertormed on the Kromasil-C18 column(250 mm ×4.6mm,5μm) with methanol-0.05% phosphoric acid solution(80:20) as the mobile phase at a flow rate of 1.0 mL/min. The detection wavelength was at 317 nm. Results The linear range of febuxostat was 32.4 -48.6 μg/mL (r =0. 999 0),the average recovery rate was 99.58%, RSD = 1.13%. Conclusion This method is rapid,sensitive and accurate,which is suitable for determining the febuxostat content in Febuxostat Tablets and can be used as the quality control method of febuxostat preparations
出处 《中国药业》 CAS 2013年第6期69-70,共2页 China Pharmaceuticals
关键词 高效液相色谱法 非布司他 含量测定 HPLC febuxostat content determination
  • 相关文献

参考文献4

  • 1Okanmto K, Eger BT, Nishino T. An extremely potent inhibitor of xanthine oxidoreductase. Crystal Structure of the Enzyme - Inhibitor Complex and Mechanism of Inhibition [J]. J Biol Chem,2003,278 (3) : 1 848 - 1 855.
  • 2Komoriya K, Osada Y, Hasegaw M, et al. Hypouricemie eftct of allopurinoI and the novel xanthine oxidase inhibitor TEI- 6720 in chimpanzees[J]. European Journal of Pharmacology, 1993,250:455 - 460.
  • 3牟卫伟.新型抗痛风药——非布索坦[J].齐鲁药事,2010,29(7):444-445. 被引量:4
  • 4唐春雷,王德才,陈姝,黄昕明.新型抗痛风药物非布索坦[J].中国新药杂志,2009,18(7):577-581. 被引量:16

二级参考文献25

  • 1MASSEY V, KOMAI H, PALMERr G, et al. On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[ 3,4-d ] pyrimidines [ J ]. J Biol Chem, 1970, 245 ( 11 ) :2837 - 2844.
  • 2HORIUCHI H, OTA M, NISHIMURA S, et al. Allopurinol induces renal toxicity by impairing pyrimidine[J]. Life Sci, 2000, 66(21) :2051 -2070.
  • 3TAKANOB Y, HASE-AOKI K, HORIUCHI H, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthlne oxidase/ xanthine dehydrogenase [ J ]. Life Sci, 2005, 76 (16) : 1835 - 1847.
  • 4OSADA Y, TSUCHIMOTO M, FUKUSHIMA H, et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents[J]. Eur J Pharmacol, 1993, 241(2-3) :183-188.
  • 5HORIUCHI H, OTA M, KOBAYASHI M, et al. A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats[ J]. Res Commun Mol Pathol Pharmacol, 1999, 104 ( 3 ) :307 - 319.
  • 6KOMORIYA K, OSADA Y, HASEGAWA M, et al. Hypouricemic effect of allopurinol and the novel xanthine oxldase inhibitor TE145720 in chimpanzees [ J ]. Eur J Pharmacol, 1993, 250 (3) :455 -460.
  • 7GRABOWSKI BA, VERNILLET L, KHOSRAVAN R, et al. Metabolism and excretion of [ ^14C ] febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in healthy male subjects [ J ]. Drug Metab Rev, 2005, 37 ( Suppl 2) : S111.
  • 8KHOSRAVAN R, KUKULKA M, WU JT, et al. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase[J]. J Clin Pharmacol, 2008, 48 : 1014 - 1025.
  • 9KHOSRAVAN R, GRABOWSKI BA. , WU JT, et al. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects [ J ]. Clin Pharmacokinet, 2006, 45 (8) :821 -841.
  • 10KHOSRAVAN R, GRABOWSKI, B, WU JT, et al. Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects[ J]. Br J Clin Pharmacol, 2008, 65 (3) :355 -363.

共引文献18

同被引文献49

  • 1陈光亮,王琳琳,徐叔云.防治痛风的药物研究进展[J].国外医学(内分泌学分册),2005,25(4):277-279. 被引量:15
  • 2马春燕.高效液相色谱法测定盐酸普萘洛尔片含量[J].中国药师,2005,8(8):637-638. 被引量:12
  • 3朱深银,周远大,杜冠华.防治痛风药物的研究进展[J].医药导报,2006,25(8):803-806. 被引量:31
  • 4Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 AmericanCollege of Rheumatology guidelines for management of gout. Part1: systematic on pharmacologic and pharmacologic therapeuticapproaches to hyperuricemia[J]. Arthritis Care Res (Hoboken),2012, 64(10): 1431-1446.
  • 5Okamoto K, Eger BT, Nishino T, et al. An extremely potentinhibitor of xanthine oxidoreductase. Crystal structure of theenzyme-inhibitorcomplex and mechanism of inhibition[J]. J BiolChem, 2003, 278(3): 1848-1855.
  • 6Canivet J, Yamaguchi J, Ban I,et a I. Nickel-catalyzed biarylcoupling of heteroarenes and arylhalides/triflates[J]. OrgLett, 2009,11(8): 1733-1736.
  • 7Komiyama M. Method for producing phenyl substitutedheterocyclic derivative by means of coupling method using apalladium compound[P]. WO 2012 026 565, 2012-03-01.
  • 8Khosravan R, Grabowski B, Wu JT, et al. Pharmacokinetics,pharmacodynamics and safety of fubuxostat, a non-purine selectiveinhibitor of xanthine oxidase, in a dose escalation study in healthysubjects[J]. Clin Pharmacokinet, 2006, 45: 821-841.
  • 9Khosravan R, Grabowski BA, Wu JT, et al. Effect of food or antacidon pharmacokinetics and pharmacodynamics of febuxostat inhealthy subjects[J]. Br J Clin Pharmacol, 2007, 65: 355-363.
  • 10Khosravan R, Grabowski B, Wu JT, et al Effect of food or antacidon pharmacokinetics and pharmacodynamics of febuxostat inhealthy subjects[J], Br J Clin Pharmacol, 2008, 65(3): 355-363.

引证文献5

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部